Revlimid® (lenalidomide)
Patient Card

2019 © Celgene Corporation

Patient Card for Revlimid® (lenalidomide)

Patient Name, or Initials or Patient unique code/identifier:

Date of Birth or Year of Birth or Age Group: [   ]
DD/MM/YYYY

Physician Name (PRINT):
Address (PRINT):
Phone number:

Physician to complete each section.

1. Indication:

Multiple Myeloma:

☐ ndMM
☐ After at least one prior therapy: Line of therapy…………
☐ Monotherapy for maintenance after autologous stem cell transplantation

Myelodysplastic Syndromes with isolated del5q cytogenetic abnormality:

☐ Low- or ☐ intermediate-1 risk

Mantle cell lymphoma relapsed and/or refractory: ☐

Other: ☐ Specify…………………………………..

2. Status of Patient (tick one)

- Male ☐
- Woman of non-childbearing potential* ☐
- Woman of childbearing potential ** ☐

(**Please also complete section 3)

Copy of Patient Card to be given to patient.

 2019 © Celgene Corporation

3. For Woman of Childbearing potential[a]

Date of Current Visit	Patient is using at least one effective method of contraception (Check one)	Pregnancy Test Date	Pregnancy Test Result (Check one)	Date of lenalidomide prescription	Physician name (PRINT)	Physician signature
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			

2019 © Celgene Corporation

Date of Current Visit	**Patient is using at least one effective method of contraception** **(Check one)**	**Pregnancy Test Date**	**Pregnancy Test Result** **(Check one)**	**Date of lenalidomide prescription**	**Physician name (PRINT)**	**Physician signature**
	☐ Yes ☐ No. Specify reason: ________________________ ☐ Unknown. Specify reason: ________________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ________________________ ☐ Unknown. Specify reason: ________________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ________________________ ☐ Unknown. Specify reason: ________________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ________________________ ☐ Unknown. Specify reason: ________________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			

2019 © Celgene Corporation

Date of Current Visit	**Patient is using at least one effective method of contraception (Check one)**	**Pregnancy Test Date**	**Pregnancy Test Result (Check one)**	**Date of lenalidomide prescription**	**Physician name (PRINT)**	**Physician signature**
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			
	☐ Yes ☐ No. Specify reason: ____________________ ☐ Unknown. Specify reason: ____________________		☐ Positive ☐ Negative ☐ Inconclusive ☐ Not done. Specify reason:			

[a] Women of childbearing potential must have a medically supervised negative pregnancy test prior to issuing a prescription (with a minimum sensitivity of 25 mIU/ml) once she has been established on contraception for at least 4 weeks, at least in 4 weekly intervals during therapy (this includes dose interruptions) and at least 4 weeks after the end of therapy (unless confirmed tubal sterilisation). This includes those women of childbearing potential who confirm absolute and continued abstinence. For further information, refer to the Summary of Product Characteristics.

2019 © Celgene Corporation

4. Counselling regarding the expected human teratogenicity of lenalidomide and the need to avoid pregnancy has been provided to the patient before first prescription

Print name	Physician's Signature

Date
DD/MM/YYYY

 2019 © Celgene Corporation